<SEC-DOCUMENT>0001193125-25-174456.txt : 20250924
<SEC-HEADER>0001193125-25-174456.hdr.sgml : 20250924
<ACCEPTANCE-DATETIME>20250806160849
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-25-174456
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pharvaris N.V.
		CENTRAL INDEX KEY:			0001830487
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		PROVINCE COUNTRY:   	P7
		BUSINESS PHONE:		31 (0)71 203 6410

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		PROVINCE COUNTRY:   	P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pharvaris, B.V.
		DATE OF NAME CHANGE:	20201029
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g79845g0805203030202.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pharvaris N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Emmy Noetherweg 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2333
BK Leiden </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August
6, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>VIA EDGAR </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and
Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office
of Life Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Eric Atallah and Kevin Kuhar </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Re:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pharvaris N.V.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for Fiscal Year Ended December&nbsp;31, 2024</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>File
<FONT STYLE="white-space:nowrap">No.&nbsp;001-40010</FONT></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Atallah and Mr.&nbsp;Kuhar: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter sets forth the response of Pharvaris N.V. (the &#147;<U>Company</U>&#148;) to the comment letter dated July&nbsp;24, 2025 from the staff of the
Division of Corporate Finance (the &#147;<U>Staff</U>&#148;) of the U.S. Securities and Exchange Commission regarding the Company&#146;s annual report for fiscal year ended December&nbsp;31, 2024 on Form <FONT STYLE="white-space:nowrap">20-F,</FONT>
filed on April&nbsp;7, 2025 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40010)</FONT> (&#147;<U>Form <FONT STYLE="white-space:nowrap">20-F</FONT></U>&#148;), transmitted to Berndt Modig, Chief Executive Officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For your convenience, set forth below is the text of the Staff&#146;s comment and the Company&#146;s response thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Form <FONT STYLE="white-space:nowrap">20-F</FONT> for Fiscal Year Ended December&nbsp;31, 2024 </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Item 4. Information on the Company </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>B. Business
Overview, page 44 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Staff&#146;s comment</I></B>: <I>We note your inclusion of a molecule named &#147;PHAXXX&#148; for an
undisclosed indication in your pipeline table on page 47. In future filings, please clarify if this refers to a specific molecule you are currently developing or if it is a placeholder for future programs in early development. If it does refer to a
specific molecule, please revise future filings to provide more fulsome disclosure related to this molecule, including the intended indication and any development steps you have undertaken. To the extent it is a placeholder, tell us why it is
sufficiently material to your business to warrant inclusion in your pipeline table. Alternatively, remove any programs that are not currently material to your business from your pipeline table in future filings.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Response</I></B>:<B> </B>The Company respectfully acknowledges the Staff&#146;s comment. PHAXXX is in early-stage development for a
confidential indication. In response to the Staff&#146;s comment, the Company will remove the inclusion of PHAXXX from the pipeline table in future filings, because the program is currently not material to our business. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Item 5. Operating and Financial Review and Prospects </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Research and development expenses, page 87 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Staff&#146;s comment</I></B><I>: We note that during 2024 both of your product candidates IR and XR began Phase 3 clinical trials.
Please tell us and revise future filings to disclose the costs incurred during each period presented for each of your key research and development product candidates. If you do not track your research and development costs by project, disclose that
fact and explain why you do not maintain and evaluate research and development costs by project in future filings. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Response</I></B>:<B> </B>The Company respectfully acknowledges the Staff&#146;s comment. Below is the draft research and development
(&#147;<U>R&amp;D</U>&#148;) expenses table the Company intends to include in its future filings, beginning with the quarterly financials on Form <FONT STYLE="white-space:nowrap">6-K</FONT> for the third quarter of 2025. In addition to such
quantitative disclosure, if the Company has any qualitative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> insights of management related to the R&amp;D expenses of its key product candidates on a
disaggregated basis, then it intends provide additional narrative disclosure. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>[Current&nbsp;Period]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>[Prior&nbsp;Period]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2"><B>(in &#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Project Specific Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>IR</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>XR</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unallocated Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I></I><I></I><I></I><I></I>Personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I></I><I></I><I></I><I></I>Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hope that the foregoing has been responsive to the Staff&#146;s comment. If you have any questions, please contact Sophia
Hudson, P.C. at (212) <FONT STYLE="white-space:nowrap">446-4750</FONT> or Jennifer L. Lee, P.C. at (212) <FONT STYLE="white-space:nowrap">909-3021,</FONT> each of Kirkland&nbsp;&amp; Ellis LLP, counsel to the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Pharvaris N.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Berndt Modig</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Berndt Modig</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sophia Hudson, P.C. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jennifer L. Lee, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Kirkland&nbsp;&amp; Ellis LLP</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g79845g0805203030202.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g79845g0805203030202.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A .<# 2(  A$! Q$!_\0
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MUT5<+'ZK[)?$E<Y,/CZGU[V\O@D[?UZ:'KLG^J?_ '37B,FIZAY[@7UU]X@
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MW]*B^)/_ !XV7_74_P J[5BJOUWV5_=O^AYKP&'66>WY?>MO=]QGPU_U-_\
M[R?UK%\=ZC]MU\P*V8[9=@_WCR?Z5H^!KR.PTC5[IR L05OT-<E;13:QJZ1;
MOWUS+R?0D\FM*5-?6ZE66R_R,*]9_P!GT</'>5_S?ZG0V.M:+!X1ETJ7S_/F
M#,S"/@-VYS]*S?">H_V;X@MW8XCD/EO]#72_\*T'_04/_?C_ .RKC]8TV31=
M6DM&DW&,@J^,9'8U5&6'K<].G*_-JR,3#&8=TZM6"2A9*UO\ST;Q]_R++_\
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GY \_TKS'PW_R,D?^\:**[,O_ -WJ'G9O_O='U_4]@HHHKQCZ0__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
